RU2756125C1 - Method for complex therapy of mastitis in lactating cows - Google Patents

Abstract

FIELD: veterinary medicine.SUBSTANCE: invention relates to veterinary medicine and applies to a method for complex therapy of mastitis in lactating cows, including intracisternal administration of an antimicrobial preparation primalact 5 ml once a day 3 to 4 times and parenteral administration of an aminosilicone preparation, wherein recombinant bovine α- and γ-interferons are additionally intramuscularly administered at a dose of 7.5 ml with a total activity of 104TCD50/cm3per animal on 1, 2 and 3 days of treatment simultaneously with intramuscular introduction of aminosilicone at a dose of 2.5 ml.EFFECT: provides an increase in the effectiveness and a reduction in the duration of treatment of mastitis in lactating cows.1 cl, 2 tbl, 1 ex

Description

The invention relates to veterinary medicine, in particular to veterinary obstetrics, and can be used for the complex therapy of mastitis in lactating cows.

The relevance of the proposed method is determined by the high incidence of mastitis in cows, which tends to grow and is up to 80%.

In meeting the needs of the population of the country in food products of animal origin, an important place is given to dairy cattle breeding. Among the many problems of the industry, the problem of the occurrence of inflammation of the mammary gland in cows - mastitis, the main causative agents of which are Staphylococcus aureus, Escherihia coli, Streptococcus spp. [Sankar P. New therapeutic strategies to control and treatment of bovine mastitis // Vet. Med. Open J. - 2016. - №1 (2). - P. 7-8].

The high incidence of cows with mastitis causes significant economic damage to dairy farming as a result of a decrease in milk production, milk quality, premature culling, treatment costs, diseases of newborn calves [Ryaposova MV, Tarasenko MN Quarterly information and analytical journal. Regulatory issues in veterinary medicine. St. Petersburg, No. 3, S. 154-157 (2014)].

In the occurrence and spread of inflammatory diseases of the mammary gland of cows, an important role is played by factors that reduce the resistance of the mammary gland and the body as a whole [Konopeltsev I.G. Russian veterinary journal No. 5, pp. 33-35 (2007)].

For the treatment of cows with mastitis, various antimicrobial drugs are produced, mainly based on antibiotics. However, as practice has shown, their irrational and long-term use contributes to the acquisition of drug resistance by microorganisms and does not provide the expected results.

In this regard, it becomes necessary to create new treatment regimens for mastitis in cows that increase the immune reactivity of the body, shorten the time and increase the effectiveness of treatment of mastitis in cows.

A known method of treating mastitis in cows with the drug Cobactan LC, containing in its composition cefkin and an oil base with the following ratio of components: cefkin sulfate - 75.0 mg, oil base up to 8 ml. The dose of administration is 8 ml into the teat tank with an interval of 12 hours until complete recovery [Instructions for the use of Cobactan LC Registration number PVI -3-4.7 / 02201].

The disadvantage of this drug is that it contains only one antibacterial agent - cefkinoma sulfate. In this regard, this drug cannot provide a high therapeutic effect in the treatment of mastitis, since with prolonged use of it, resistance rapidly forms in microorganisms - pathogens of mastitis.

A known method of treating mastitis in cows using the placenta denatured emulsified (PDE) [Veterinary drugs in Russia: Handbook / I.F. Klenova, N.A. Yaremenko. - M .: Selkhozizdat, 2000. - S. 446].

But, as you know, the biogenic stimulant PDE does not have either a bactericidal or bacteriostatic effect, and with inflammation of the mammary gland of cows, in particular, with mastitis, various opportunistic bacteria and fungi are released. Due to this fact, the drug does not give the desired effect.

A known method of treating mastitis in lactating cows with an antimicrobial drug based on staphylococcal bacteriophages when administered intercisternally at a dose of 50 ml to each affected lobe once for 3 days [Niyaz N.M. The basics of obtaining staphylococcal bacteriophage for the treatment of cow mastitis. Dis. Cand. vet. sciences. - Moscow, 1988. - S. 73.].

The disadvantages of the drug include the lack of immunostimulating action and low therapeutic effect.

Thus, for the treatment of mastitis in cows, a complex method of treatment is required, including the use of antimicrobial agents and biogenic stimulants, which have a beneficial effect both on the focus of inflammation and on the animal's body, which makes it possible to increase the effectiveness of treatment and shorten its duration.

A known method of complex treatment of mastitis in lactating cows [RU 2519349 C1, A61K 35/28, A61K 31/00, A61K 31/19, A61K 31/573, A61P 15/00, 06/10/2014. Bul. No. 16]. The method includes subcutaneous administration of a biogenic stimulant and intracisternal - etiotropic agent. According to the invention, an etiotropic agent, an antimicrobial drug masticef, is injected intracisternally at a dose of 5 ml with a 24-hour interval of 2-4 times, and as a biogenic stimulator, a drug obtained from the spleen of pigs (BSS) is used by homogenization with ultrasound, heating the homogenate and its cooling, sedimentation supernatant followed by removal of ballast proteins by centrifugation or ultrafiltration, and a biogenic stimulator is injected into the upper third of the neck on days 1-3-5-7 of treatment at a dose of 30-35-40-45 ml, respectively.

The disadvantage of this method is that it requires a long (sevenfold) introduction of a biogenic stimulant and the use of large doses of it (30-35-40-45 ml).

As a prototype, a method of treating mastitis in cows during lactation with the use of the antimicrobial drug Primalact by intracisternal administration once a day 3-4 times (until clinical recovery), and the drug aminoseleton, which is injected into the upper third of the neck in 1-3-5 -7 days of treatment at a dose of 30-35-40-45 ml [Klimov, N.T. The effectiveness of the use of nonspecific pathogenetic and antimicrobial therapy for mastitis in cows / N.T. Klimov, S.S. Pershin and V.I. Zimnikov, A.V. Chursin // Topical issues of veterinary pharmacology, toxicology and pharmacy: materials of the IV Congress of veterinary pharmacologists and toxicologists of Russia. - M., 2013 .-- S. 318-320.

However, this method does not have a high enough therapeutic efficacy. This requires long-term treatment (7 days) and the use of large doses of biogenic stimulant (30-35-40-45 ml).

The technical result of the invention is to improve the efficiency and shorten the treatment time for mastitis in lactating cows.

The technical result is achieved by the fact that in the method of complex therapy of mastitis in lactating cows, including intracisternal administration of the antimicrobial drug primalact, 5 ml once a day 3-4 times and parenteral administration of the drug aminoseleton, according to the invention, simultaneously with intramuscular administration of aminoseleton at a dose of 2, 5 ml additionally intramuscularly injected bovine recombinant α- and γ-interferons at a dose of 7.5 ml with a total activity of 10 ⁴ TCD _{50 / cm} ³ per animal on days 1, 2 and 3 of treatment.

Available in the claimed method, the synergistic nature of the antibacterial action, as well as immunostimulating, antioxidant, anti-inflammatory and regenerative, provides a high therapeutic effect.

Bovine recombinant interferon is a species-specific drug that has immunostimulating and antiviral activity in cattle. The effect of the drug is determined by the total effect of the exogenous protein on the affected cells and the rapid induction of the endogenous interferon system, cellular and humoral immunity. Bovine recombinant interferon acts as an inducer of lysozyme and bactericidal activity of blood serum. Has anti-inflammatory effect. Increases the resistance of the animal organism to the effects of DNA and RNA-containing viruses and pathogenic microorganisms Registration certificate No. 4950-10-15BPH-F from 15.07.15].

Checking the effectiveness of the method for treating mastitis in cows during lactation was carried out on black-and-white cows with an annual milk yield for the previous lactation of 6000-7000 kg of milk belonging to LLC SP Vyaznovatovka, Voronezh region. The diagnosis of mastitis was established in accordance with the "Manual for the diagnosis, therapy and prevention of mastitis in cows" (M., 2000).

The essence of the technical solution is illustrated by examples.

The studies were carried out on 42 patients with clinically pronounced catarrhal and 34 purulent-catarrhal mastitis, which were divided into two subgroups according to the analogy principle. All animals of the first group (baseline) were treated with the antimicrobial drug Primalact [Instructions for use of the veterinary drug Primalact, Registration Certificate 15-3-7.19-4477 No. PVR-3-32.13 / 03012], which was administered intracisternally at 5 ml once a day 3-4 times (until clinical recovery), and aminoseleton, which was injected into the upper third of the neck on 1-3-5-7 days of treatment at a dose of 30-35-40-45 ml.

Animals of the second subgroup (the inventive method) on days 1, 2 and 3 of treatment were parenterally administered aminoseleton at a dose of 2.5 ml, bovine recombinant α- and γ-interferons at a dose of 7.5 ml (with a total activity of 10 ⁴ TCD _{50 / cm} ³ ) per animal and etiotropic drug Primalact, which was administered intracisternally once a day 3-4 times (until clinical recovery).

Evaluation of the effectiveness of the use of drugs was carried out on the basis of clinical recovery, bacteriological studies (degree of microbial contamination, species composition of microflora) of the udder secretion and determination of the content of somatic cells in it, selected from the affected lobes before the experiment and 7 days after the end of treatment. The research results are presented in table 1.

It was found that the use of the basic treatment option (primalact + aminoseleton) led to the recovery of 85.7% of cows with catarrhal mastitis, while 91.7% of the udder lobes were cured.

The best therapeutic effect was achieved with the combined use of primalact, aminoseleton and recombinant bovine interferons. The effectiveness of this method of treatment for catarrhal mastitis was 95.2%, which is higher than when using the basic variant by 9.5%, and with purulent-catarrhal mastitis - 88.2%, which is 11.7% higher than when using the basic variant %.

The obtained data on the increase in the effectiveness of the treatment of cow mastitis using the proposed method is confirmed by the data on the bacteriological study of milk and the determination of the content of the level of somatic cells in it after the end of the course of treatment. The research results are presented in table 2.

It was found that in the group of animals, where bovine recombinant interferons were additionally used, the number of animals that remained bacteria carriers was 1.9 times lower than in the animals of the basic variant, the content of somatic cells in them was also 1.6 times lower.

Consequently, the additional introduction of bovine recombinant interferons into the treatment regimen for clinically expressed catarrhal mastitis increases the therapeutic effect of the antimicrobial drug and reduces the number of animals that remain bacterial carriers.

Claims (1)

A method of complex therapy for mastitis in lactating cows, including intracisternal administration of the antimicrobial drug Primalact, 5 ml once a day 3-4 times and parenteral administration of the drug Aminoseleton, characterized in that simultaneously with the intramuscular administration of Aminoseleton in a dose of 2.5 ml, bovine is additionally injected intramuscularly recombinant α- and γ-interferons in a dose of 7.5 ml with a total activity of 10 ⁴ TCD _{50 / cm} ³ per animal on days 1, 2 and 3 of treatment.